The firm is planning a hybrid approach to clinical translation, including launching some of its own cancer tests and licensing technology to other labs.
The net proceeds will support continued product development, research, product commercialization, working capital, and other general corporate purposes.
The firm expects to launch a 510(k)-cleared version of its Bladder EpiCheck recurrence assay early next year followed by an RUO early-stage lung cancer assay.
The clinical genome-wide DNA methylation test can diagnose genetic diseases that are missed by exome or genome sequencing and evaluate variants of unknown significance.
The JHU technology leverages an epigenetic biomarker panel and a sponge-on-a-string collection device, as well as a PCR-based method, to detect Barrett's esophagus.
